PDF(Pubmed)
Abstract：
UNASSIGNED: This observational study aimed to investigate the incidence of herpes zoster (HZ) among at-risk subjects aged ≥50 years, characterize them and assess annual healthcare utilization and costs from the Italian National Health System (NHS) perspective.
UNASSIGNED: Records of reimbursed drug prescriptions, hospitalizations and outpatient specialist care from the Fondazione ReS database were linked to identify patients aged ≥50 years at HZ risk (i.e. cardiovascular disease/chronic obstructive pulmonary disease/diabetes/immunosuppression, according to the Italian National Vaccine Prevention Plan - PNPV 2017-2019) in 2013. New HZ events (incidence per 1,000) were researched in 2 years, and subjects with HZ in the previous year were excluded. Antiviral and pain therapy consumptions, hospitalizations for HZ and costs paid by NHS were assessed annually.
UNASSIGNED: From 12,562,609 inhabitants in 2013, a total of 1,004,705 patients (18.5% aged ≥50 years) at risk without a previous event were selected. The 2-year incidence of HZ was 5.9 per 1,000 (mean age 74 ± 10 years; 54.3% female). Patients aged 80-89 (7.2 per 1,000), females (6.7 per 1,000) and immunosuppressed subjects (6.9 per 1,000) had the highest incidence rates. One year after the new HZ episode, 82.2% were treated with specific antivirals (79.3% brivudine), generating an annual average cost/treated of €106; 8.0% were hospitalized for HZ, with an average cost/hospitalized of €3,927; the overall mean cost/incident patient was €402.
UNASSIGNED: This analysis provided HZ incidence in subjects aged ≥50 years considered at risk by the PNPV and its burden from the NHS perspective. Our findings can help health governance to improve clinical decisions and economic positioning concerning zoster vaccine plan.
UNASSIGNED: Records of reimbursed drug prescriptions, hospitalizations and outpatient specialist care from the Fondazione ReS database were linked to identify patients aged ≥50 years at HZ risk (i.e. cardiovascular disease/chronic obstructive pulmonary disease/diabetes/immunosuppression, according to the Italian National Vaccine Prevention Plan - PNPV 2017-2019) in 2013. New HZ events (incidence per 1,000) were researched in 2 years, and subjects with HZ in the previous year were excluded. Antiviral and pain therapy consumptions, hospitalizations for HZ and costs paid by NHS were assessed annually.
UNASSIGNED: From 12,562,609 inhabitants in 2013, a total of 1,004,705 patients (18.5% aged ≥50 years) at risk without a previous event were selected. The 2-year incidence of HZ was 5.9 per 1,000 (mean age 74 ± 10 years; 54.3% female). Patients aged 80-89 (7.2 per 1,000), females (6.7 per 1,000) and immunosuppressed subjects (6.9 per 1,000) had the highest incidence rates. One year after the new HZ episode, 82.2% were treated with specific antivirals (79.3% brivudine), generating an annual average cost/treated of €106; 8.0% were hospitalized for HZ, with an average cost/hospitalized of €3,927; the overall mean cost/incident patient was €402.
UNASSIGNED: This analysis provided HZ incidence in subjects aged ≥50 years considered at risk by the PNPV and its burden from the NHS perspective. Our findings can help health governance to improve clinical decisions and economic positioning concerning zoster vaccine plan.
摘要：
未经评估：这项观察性研究旨在调查50岁以上高危人群中带状疱疹（HZ）的发病率。从意大利国家卫生系统（NHS）的角度对其进行表征并评估年度医疗保健利用率和成本。
未经批准：报销的药物处方记录，来自FondazioneReS数据库的住院和门诊专科护理被链接以识别年龄≥50岁的患者在HZ风险(即心血管疾病/慢性阻塞性肺疾病/糖尿病/免疫抑制,根据意大利国家疫苗预防计划-PNPV2017-2019），2013年。在2年内研究了新的HZ事件(每1000人的发病率)，前一年有HZ的受试者被排除在外。抗病毒和疼痛治疗的消耗，每年评估HZ的住院治疗和NHS支付的费用。
UNASSIGNED：从2013年的12,562,609名居民中，总共选择了1,004,705名患者（18.5％年龄≥50岁），没有先前事件。HZ的2年发病率为5.9/1000（平均年龄74±10岁；54.3％为女性）。80-89岁的患者（7.2/1000），女性(6.7/1,000)和免疫抑制受试者(6.9/1,000)的发病率最高.新的HZ剧集一年后，82.2％的人使用特异性抗病毒药物（79.3％的溴夫定），产生的年平均费用/治疗为106欧元；8.0%因HZ住院，平均费用/住院3,927欧元;总体平均费用/事件患者为402欧元.
UNASSIGNED：该分析提供了年龄≥50岁的受试者的HZ发生率，该受试者被PNPV及其负担从NHS的角度考虑。我们的发现可以帮助卫生治理改善有关带状疱疹疫苗计划的临床决策和经济定位。
未经批准：报销的药物处方记录，来自FondazioneReS数据库的住院和门诊专科护理被链接以识别年龄≥50岁的患者在HZ风险(即心血管疾病/慢性阻塞性肺疾病/糖尿病/免疫抑制,根据意大利国家疫苗预防计划-PNPV2017-2019），2013年。在2年内研究了新的HZ事件(每1000人的发病率)，前一年有HZ的受试者被排除在外。抗病毒和疼痛治疗的消耗，每年评估HZ的住院治疗和NHS支付的费用。
UNASSIGNED：从2013年的12,562,609名居民中，总共选择了1,004,705名患者（18.5％年龄≥50岁），没有先前事件。HZ的2年发病率为5.9/1000（平均年龄74±10岁；54.3％为女性）。80-89岁的患者（7.2/1000），女性(6.7/1,000)和免疫抑制受试者(6.9/1,000)的发病率最高.新的HZ剧集一年后，82.2％的人使用特异性抗病毒药物（79.3％的溴夫定），产生的年平均费用/治疗为106欧元；8.0%因HZ住院，平均费用/住院3,927欧元;总体平均费用/事件患者为402欧元.
UNASSIGNED：该分析提供了年龄≥50岁的受试者的HZ发生率，该受试者被PNPV及其负担从NHS的角度考虑。我们的发现可以帮助卫生治理改善有关带状疱疹疫苗计划的临床决策和经济定位。
